Objective To develop the Expert consensus on nursing care and case management for novel weight‑loss drug therapy (2026 edition) (hereinafter referred to as the Consensus), with the aim of standardizing and optimizing clinical nursing care and case management processes for novel anti‑obesity medications, represented by glucagon‑like peptide‑1 (GLP‑1) receptor agonists and their dual or multi‑receptor agonists.

Methods Based on systematic literature retrieval and evidence-based medicine evaluation, an initial pool of management items was generated. Two rounds of modified Delphi expert consultation were conducted to rate the importance and assess the consensus of these items. By integrating evidence levels with expert opinions, a stepwise clinical nursing management pathway was constructed.

Results Following two rounds of expert consultation, seven core management domains were established, encompassing a total of 86 items. The Consensus outlines key components, including pre‑treatment assessment and patient education, strategies to enhance adherence, essential elements of lifestyle intervention, monitoring and graded management of adverse events, efficacy evaluation indicators, multidisciplinary collaboration processes, and mana-gement of special populations. These components collectively form a clinically applicable nursing management pathway and operational framework.

Conclusion Based on evidence‑based medicine and expert consensus, the Consensus establishes a standardized framework for nursing care and management in novel anti‑obesity pharmacotherapy, providing a normative reference for clinical practice.